On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.

On the news front, the company announced on June 4 that the new drug application for KJ103 for injection was accepted by China's National Medical Products Administration, designated for desensitization therapy in highly sensitized kidney transplant patients. The product was granted priority review status on May 20. KJ103 is a global first-in-class low-immunogenicity IgG-degrading enzyme. Phase III clinical data demonstrated a 100% pre-transplant desensitization success rate and 100% kidney transplant success rate, with graft survival exceeding 100% at three months.

The broader biotechnology sector also showed recovery today, with AKESO up 2.87%, Innovent Biologics up 3.66%, SKB Bio up 7.28%, and Remegen up 2.07%, providing additional tailwind for individual stock performance following prior sector-wide weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)